{
  "name": "Regulatory Definitions and Research Incentives for Rare Disease Therapeutics Across Global Jurisdictions",
  "description": "Comparative compilation of statutory rare disease prevalence thresholds, exclusivity incentives, and protocol support mechanisms across major health authorities (FDA, EMA, MHLW Japan, TGA Australia, Health Canada, UK MHRA). Compiled from regulatory statutes and agency guidance documents.",
  "page": "https://casrai.org/guides/rare-disease-research",
  "publisher": "CASRAI",
  "license": "https://creativecommons.org/licenses/by/4.0/",
  "dateModified": "2026-11-15T01:32:37Z",
  "temporalCoverage": "2024/2026",
  "spatialCoverage": "Global",
  "columns": [
    {
      "name": "Jurisdiction",
      "unit": "",
      "description": "Country or regional governing body"
    },
    {
      "name": "Governing Statute or Policy",
      "unit": "",
      "description": "Primary legislative act or orphan designation framework"
    },
    {
      "name": "Statutory Prevalence Threshold",
      "unit": "",
      "description": "Numerical cutoff or ratio defining rare condition status"
    },
    {
      "name": "Approximate Population Rate",
      "unit": "cases per 10,000",
      "description": "Standardized population prevalence ratio"
    },
    {
      "name": "Market Exclusivity Period",
      "unit": "years",
      "description": "Statutory regulatory data protection or market exclusivity"
    },
    {
      "name": "Regulatory Protocol Support",
      "unit": "",
      "description": "Official scientific advice or protocol assistance mechanisms"
    }
  ],
  "rows": [
    {
      "Jurisdiction": "United States",
      "Governing Statute or Policy": "Orphan Drug Act of 1983 (21 CFR Part 316)",
      "Statutory Prevalence Threshold": "< 200,000 total prevalence nationwide",
      "Approximate Population Rate": 6,
      "Market Exclusivity Period": 7,
      "Regulatory Protocol Support": "FDA Protocol Assistance, CDER/CBER Rare Disease Hub, user fee waivers"
    },
    {
      "Jurisdiction": "European Union",
      "Governing Statute or Policy": "Regulation (EC) No 141/2000",
      "Statutory Prevalence Threshold": "",
      "Approximate Population Rate": 5,
      "Market Exclusivity Period": 10,
      "Regulatory Protocol Support": "EMA Committee for Orphan Medicinal Products (COMP) protocol assistance, fee reductions"
    },
    {
      "Jurisdiction": "Japan",
      "Governing Statute or Policy": "Pharmaceuticals and Medical Devices Act (Art. 77-2)",
      "Statutory Prevalence Threshold": "< 50,000 total patients nationwide",
      "Approximate Population Rate": 4,
      "Market Exclusivity Period": 10,
      "Regulatory Protocol Support": "PMDA priority consultation, NIBIOHN research subsidies up to 50%"
    },
    {
      "Jurisdiction": "United Kingdom",
      "Governing Statute or Policy": "Human Medicines Regulations (Orphan Designation Scheme)",
      "Statutory Prevalence Threshold": "",
      "Approximate Population Rate": 5,
      "Market Exclusivity Period": 10,
      "Regulatory Protocol Support": "MHRA Innovative Licensing and Access Pathway (ILAP), fee waivers"
    },
    {
      "Jurisdiction": "Australia",
      "Governing Statute or Policy": "Therapeutic Goods Regulations 1990 (Orphan Drug Program)",
      "Statutory Prevalence Threshold": "",
      "Approximate Population Rate": 5,
      "Market Exclusivity Period": 5,
      "Regulatory Protocol Support": "TGA priority evaluation pathway, full evaluation fee waiver"
    },
    {
      "Jurisdiction": "Canada",
      "Governing Statute or Policy": "Food and Drugs Act (Rare Diseases Drug Strategy)",
      "Statutory Prevalence Threshold": "",
      "Approximate Population Rate": 5,
      "Market Exclusivity Period": 8,
      "Regulatory Protocol Support": "Health Canada Submarket Review, priority review voucher alignment"
    }
  ],
  "sources": [
    {
      "title": "FDA Designating an Orphan Product: Drugs and Biological Products",
      "url": "https://www.fda.gov/industry/developing-products-rare-diseases-conditions/designating-orphan-product-drugs-and-biological-products",
      "accessed": "2026-11-14"
    },
    {
      "title": "EMA Orphan Designation: Overview and Legal Basis (Regulation EC 141/2000)",
      "url": "https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview",
      "accessed": "2026-11-14"
    },
    {
      "title": "PMDA Orphan Drug Designation System and Review Criteria",
      "url": "https://www.pmda.go.jp/english/review-services/reviews/approved-information/drugs/0002.html",
      "accessed": "2026-11-14"
    }
  ]
}